This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

The Clinical Trials Industry’s Weekly News Update

TrialHub teams with Emvenio and MCRA

Share this article

TrialHub has entered into partnerships with UK based trials contractor MCRA and US mobile trials firm Emvenio.

The deal with MCRA – finical terms of which were not disclosed – is focused on TrialHub’s AI-powered system, which provides “real-time insights on sites, competition, patients and regulations” according to the firm.

MCRA’s vice president of clinical affairs, Abigail Allen, said "Collaborating with TrialHub has allowed our clinical team to improve our research capabilities. We look forward to continuing to explore the opportunities TrialHub presents for both our clients and the entire MCRA organization."

In a press statement MCRA said the partnership strengthens its commitment to “driving patient-centric healthcare through informed and efficient clinical research with innovative technology, extensive real-world data sources, and detailed analytics.”

According to the UK clinical research organization (CRO), TrialHub provides an overview of the clinical research landscape in over 70 countries.

The agreement with Emvenio Research is also focused on TrialHub’s AI-technology. Through the platform, Emvenio will aim to identify optimal markets to attract trial participants to support pharmaceutical sponsors and clinical research organizations’ participation goals.

According to Emvenio president Thad Wolfram, the key benefit is the ability to interact with all parties in the research ecosystem.

“With TrialHub’s uniquely curated data, Emvenio can connect CROs and sponsors to the appropriate population of potential trial participants for a range of studies across a wide array of therapeutic areas.

“Faster and more intelligent access to data allows us to quickly identify and recommend the best communities in which to conduct a trial and activate it in a more efficient manner, saving our clients time and money and providing them the results they need sooner than later” Wolfram said.

As part of the agreement EmVenio will donate a full patient scholarship to the European Patients’ Academy on Therapeutic Innovation’s Patient Expert program, which TrialHub joined this year.

EUPATI’s program focuses on education, inclusivity and stakeholder partnership to enhance patient engagement through accessible and innovative education.


Share this article

Sign up for Clinical Insider email updates